ADVANCED SOLID TUMORS

This early-stage trial tests an experimental oral drug called ZN-A-1041, alone or with other cancer drugs, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The study aims to find safe doses and check how the drug works in …

This study is the first time PRL3-ZUMAB is being tested in humans. It aims to find a safe dose for people with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll 38 participants and monitor for side effects and drug levels in the bloo…

This early-stage trial tests two experimental mRNA therapies, mRNA-4106 and mRNA-4200, in 42 people with advanced solid tumors like melanoma, lung, liver, and ovarian cancers. The study aims to check safety and find the right dose, either alone or combined with the immunotherapy …

This early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …

This study follows people with advanced solid tumors who are already benefiting from the cancer drug spartalizumab. The goal is to keep monitoring safety and side effects over a longer period. About 120 participants will continue receiving the drug as long as it helps them.

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This early-stage trial tests a new treatment called hV01, a modified virus designed to infect and kill cancer cells while boosting the immune system. It is for people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the safety o…

This early-phase study tests a new drug, BAY 2965501, that activates immune cells to fight advanced solid tumors (like certain skin, kidney, stomach, and lung cancers). About 284 participants will receive the drug alone or with other treatments. The main goals are to check safety…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This early-phase trial is testing a drug called sotorasib, which targets a specific cancer-driving mutation (KRAS G12C), either alone or combined with other cancer therapies. About 610 adults with advanced solid tumors that have this mutation will receive treatment to see if the …

This early-phase study tests an experimental drug called AMG 355, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug sh…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants w…

This early-stage study tests an experimental pill, ATV-1601, in adults with advanced solid tumors or certain breast cancers that have a specific AKT1 gene change. The main goals are to find a safe dose and check how the drug moves through the body. About 134 participants will tak…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This study tests the drug pembrolizumab in about 1,600 people with various advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink or control the tumors. Participants receive pembrolizumab and are monitored for tumor respons…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This early-phase study tests a new drug called QTX3544, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific genetic change (KRAS G12V). The main goals are to check safety and find the right dose. About 237 adults with tumors that have…

This early-phase study tests a new form of the chemotherapy drug topotecan, wrapped in liposomes, in about 96 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and understand side effects. The study inc…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study is for adults with advanced solid tumors (like head and neck, breast, ovarian, or skin cancer) that haven't responded to standard treatments. Researchers want to understand how the drug pembrolizumab changes genes and immune markers in the blood and tumors. The goal is…